Oncology & Cancer

Durvalumab extends survival in stage III non-small cell lung CA

(HealthDay)—Durvalumab results in significantly longer overall survival than placebo among patients with stage III, unresectable non-small cell lung cancer who did not have disease progression after concurrent chemoradiotherapy, ...